Compounded semaglutide safety is really a question about pharmacies, not molecules. Semaglutide itself — the active ingredient in FDA-approved Wegovy — is one of the most studied weight-loss drugs ever, producing about 14.9% average weight loss over 68 weeks in the STEP 1 trial. But that trial tested the approved product, made under full FDA manufacturing oversight. Compounded versions are pharmacy-made copies sold for roughly $99 to $299 a month, and the FDA never reviews them for safety, effectiveness, or quality before they ship. Whether a given vial is trustworthy depends almost entirely on who made it, from what ingredient, and under which of two very different rulebooks: 503A or 503B.
Why Compounded Semaglutide Is Legal at All
Drug compounding is not a loophole — it is written into federal law. Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act allow licensed pharmacies to prepare custom medications for patients who cannot use an approved product, such as someone allergic to an ingredient or someone who needs a liquid instead of a pill.
The catch, per the FDA’s own compounding Q&A, is blunt: compounded drugs are not FDA-approved. The agency does not verify their safety, effectiveness, or quality before they are marketed. Every quality check that normally happens before a drug reaches you is either handled by the pharmacy itself or skipped.
There is a second legal wrinkle. Compounders generally may not make what amounts to a copy of an available FDA-approved drug. Mass compounding of semaglutide took off while the drug sat on the FDA’s shortage list, and the FDA declared that shortage resolved in February 2025. Since then, the legal lane has narrowed, and many telehealth programs frame their products as personalized — modified doses or added ingredients like vitamin B12 — an approach that remains contested. The practical takeaway: this market operates in a gray zone, and the burden of quality-checking falls on you.
Compounded Semaglutide Safety: What the FDA Has Reported
The FDA maintains a standing warning page about unapproved GLP-1 drugs, and it documents real harm — not hypothetical risk. The agency says it has received adverse-event reports tied to compounded semaglutide, some involving people who needed medical attention, including hospitalization.
The single biggest problem it describes is dosing errors. Compounded semaglutide typically ships as a multi-dose vial, and the FDA has received reports of people accidentally drawing 5 to 20 times the intended dose. There is no pen clicking to a fixed stop — just a syringe, a vial, and your math.
The FDA has also policed marketing in this space. In September 2025, it sent a warning letter to telehealth seller Sprout Health for claiming its compounded GLP-1s were FDA-approved — a false statement the company later corrected. In June 2026, another warning letter went to Trinity Healthcare Supply, LLC over misleading compounded GLP-1 claims on its altRx brand website. When sellers themselves misstate what these products are, buyers need to know the baseline: no compounded semaglutide product is FDA-approved, period.
None of this means every compounded vial is dangerous. It means the safety floor is not set by the FDA — it is set by the specific pharmacy that made your vial. That is where 503A versus 503B matters.
503A vs 503B: Two Very Different Rulebooks
Every legal compounding operation in the U.S. falls into one of two categories, and they are not equally supervised. Here is the difference, based on the FDA’s compounding Q&A.
| 503A compounding pharmacy | 503B outsourcing facility | |
|---|---|---|
| How it operates | Compounds per patient, per prescription | Produces large batches, with or without patient-specific prescriptions |
| FDA registration | Not required — state-licensed | Registers with the FDA |
| Manufacturing standard | Exempt from full federal cGMP | Must follow cGMP, the same framework drug manufacturers use |
| Inspections | Primarily state boards of pharmacy | FDA inspections on a risk-based schedule |
| Adverse-event reporting to FDA | Not federally required | Required |
In plain terms: a 503B outsourcing facility volunteers for oversight much closer to a real drug manufacturer — federal registration, cGMP sterile production standards, FDA inspections, and mandatory adverse-event reporting. A 503A pharmacy can be excellent, but its baseline federal requirements are lighter, and quality rests mostly on state inspections and the pharmacy’s own practices.
Telehealth providers vary widely on this. Noom Med states its compounded medication is produced at an FDA-regulated 503B outsourcing facility, per its own press release. altRx names four 503A pharmacy partners publicly. MEDVi names its pharmacies (Triad Rx, RedRock Pharmacy, Beaker Pharmacy) but does not state their 503A/503B status — and plenty of competitors name nothing at all, citing only unnamed licensed pharmacies. A provider that will not tell you who makes its drug is asking you to trust a supply chain it refuses to show you.
The Salt-Form Red Flag: Semaglutide Sodium and Acetate
This is the sharpest red flag in the entire market. The FDA has warned that some compounded products contain salt forms of semaglutide — semaglutide sodium and semaglutide acetate — which are chemically different active ingredients from the base semaglutide used in the approved drugs Wegovy and Ozempic.
The agency’s position is unusually direct: it says it is not aware of any legal basis for compounding with these salt forms that would meet federal requirements. Salt forms have not been shown to be safe or effective in humans the way base semaglutide has, and their presence usually signals a supplier cutting corners on ingredient sourcing.
Your defense is simple. Ask the provider, in writing, whether its pharmacy compounds with semaglutide base. A trustworthy operation answers instantly and can show a certificate of analysis proving it. Hesitation, vagueness, or a “proprietary formula” answer means walk away.
Dosing Errors: Where Most Injuries Start
Brand-name Wegovy comes in single-use pens with five fixed doses (0.25, 0.5, 1, 1.7, and 2.4 mg), escalated roughly every four weeks over about 16 weeks, per the Wegovy prescribing information. You cannot easily inject the wrong amount from a pen built to deliver one dose.
Compounded semaglutide removes that guardrail. Most programs ship a multi-dose vial plus insulin syringes marked in units, and your milligram dose must be converted into units based on that specific vial’s concentration — which varies from pharmacy to pharmacy. Get the conversion wrong at any of the five titration steps and you inject the wrong dose. This is exactly how the FDA’s reported 5-to-20-fold overdoses happen.
The danger compounds because overdose symptoms mimic ordinary ones. Per the Mayo Clinic, nausea and vomiting are among semaglutide’s most common side effects even at correct doses — so a serious dosing error can look, at first, like a rough week. Severe or persistent vomiting is a reason to seek medical care, not to wait it out. Our GLP-1 side effects guide covers what is normal, what is not, and when to call a doctor.
Before every dose increase, make the provider confirm your dose in both milligrams and syringe units, in writing. A program that automates refills without that check is prioritizing shipping speed over your safety.
A Compounded Semaglutide Safety Checklist: 7 Questions to Ask
Every question below has a clean answer at a well-run provider. Treat a dodge on any of them as your answer.
- Which pharmacy fills my prescription? You want a name you can verify with a state pharmacy board — not “our licensed pharmacy partners.”
- Is it a 503A pharmacy or a 503B outsourcing facility? Either can be legal; 503B means stricter federal manufacturing oversight.
- Is the product made from semaglutide base — not a salt form? Get it in writing.
- Can I see a certificate of analysis? Third-party testing for potency, sterility, and endotoxins is the strongest quality evidence a compounded drug can have. ReadyRx, for example, offers a certificate of analysis from third-party lab testing on request — proof this is a reasonable thing to ask for.
- Who reviews my health history and manages my dose? A licensed clinician should evaluate you before prescribing and before each escalation — our guide to how telehealth weight loss works explains what a legitimate review looks like.
- What is the beyond-use date, and how is the vial shipped? Compounded sterile drugs expire fast, and semaglutide needs cold-chain handling.
- What happens if I have a bad reaction? You want a real path to a clinician, not a support ticket queue.
Our comparison of the best compounded semaglutide programs tracks which providers actually answer these questions — pharmacy names, 503 status, and testing practices are scored directly in our rubric.
How Cheap Is Too Cheap?
Price pressure is what pushes people toward this market in the first place, and the pull is real: the cheapest online GLP-1 providers advertise compounded semaglutide from about $99 a month, against a list price of roughly $1,349 a month for brand-name Wegovy. That gap is life-changing money for a medication meant to be taken long term.
But the cheapest vial is only a bargain if it contains what the label says. The pattern worth internalizing from everything above: compounded semaglutide safety is a disclosure problem — price tells you nothing, paperwork tells you everything. A $199 provider that names a 503B facility and shows test results is a fundamentally different purchase than a $99 provider that hides its pharmacy. Pay for the version of this market that shows its work, or pay full price for the FDA-approved product. The one option without a case is cheap and blind.